{"id":70775,"date":"2026-07-28T18:02:20","date_gmt":"2026-07-28T10:02:20","guid":{"rendered":"https:\/\/flcube.com\/?p=70775"},"modified":"2026-07-28T18:02:21","modified_gmt":"2026-07-28T10:02:21","slug":"alexions-ultomiris-fails-to-meet-primary-endpoint-in-phase-iii-hsct-tma-trial-despite-showing-treatment-benefit-trend","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70775","title":{"rendered":"Alexion&#8217;s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Alexion<\/strong>, AstraZeneca plc&#8217;s (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) rare disease unit, announced top-line results from its <strong>Phase III ALXN1210-TMA-313 clinical trial<\/strong> evaluating <strong>Ultomiris (ravulizumab)<\/strong> in patients with <strong>hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)<\/strong>. The trial did not achieve statistical significance for its primary endpoint of event-free survival (EFS) through 26 weeks compared to placebo in adult and adolescent patients aged 12 years and older.<\/p>\n\n\n\n<h2 id=\"h-trial-overview\" class=\"wp-block-heading\">Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Sponsor<\/strong><\/td><td>Alexion, AstraZeneca plc (NYSE: AZN)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Trial ID<\/strong><\/td><td>ALXN1210-TMA-313<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adult and adolescent patients (\u226512 years) with HSCT-TMA<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Event-free survival (EFS) through 26 weeks<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Placebo<\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td>Did not achieve statistical significance<\/td><\/tr><tr><td><strong>Secondary Finding<\/strong><\/td><td>Trend toward treatment benefit at 26 weeks<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Ravulizumab (Ultomiris)<\/li>\n\n\n\n<li><strong>Class:<\/strong> Longest-acting C5 complement inhibitor<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Provides immediate, complete, and sustained complement suppression<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong><\/li>\n\n\n\n<li>Orphan Drug Designation (US FDA and Japan PMDA) for HSCT-TMA<\/li>\n\n\n\n<li>Breakthrough Therapy Designation (US FDA) for pediatric HSCT-TMA<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-iii-alxn1210-tma-313\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase III ALXN1210-TMA-313<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (Ultomiris)<\/th><th>Comparator (Placebo)<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary: Event-Free Survival<\/strong><\/td><td>Not statistically significant<\/td><td>Reference<\/td><td><strong>Missed<\/strong><\/td><\/tr><tr><td><strong>Secondary: Treatment Benefit Trend<\/strong><\/td><td>Positive directional benefit<\/td><td>Reference<\/td><td><strong>Observed<\/strong><\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Consistent with known profile<\/td><td>\u2013<\/td><td>No new safety signals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">While the trial failed to meet its primary endpoint, researchers noted a consistent trend toward treatment benefit with Ultomiris compared to placebo at the 26-week assessment point, suggesting potential clinical value that warrants further investigation.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AstraZeneca Strategy:<\/strong> The $39 billion acquisition of Alexion in 2021 underscored AstraZeneca&#8217;s commitment to rare diseases; these results may prompt strategic reassessment of Ultomiris development in HSCT-TMA.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> As the longest-acting C5 complement inhibitor, Ultomiris maintains a differentiated position despite this setback.<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Existing Orphan Drug and Breakthrough Therapy designations may support continued development despite the primary endpoint miss.<\/li>\n\n\n\n<li><strong>Investor Implications:<\/strong> AstraZeneca has not yet disclosed whether these results will impact projected market timelines or financial guidance.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial outcomes, regulatory pathways, and development strategies for Ultomiris. Actual results may differ due to risks including additional data analyses, regulatory decisions, and strategic reassessments by AstraZeneca.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alexion, AstraZeneca plc&#8217;s (NYSE: AZN) rare disease unit, announced top-line results from its Phase III&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[2461,130,17,4621],"class_list":["post-70775","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-alexion","tag-astrazeneca","tag-clinical-trial-results","tag-nyse-azn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alexion&#039;s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alexion, AstraZeneca plc&#039;s (NYSE: AZN) rare disease unit, announced top-line results from its Phase III ALXN1210-TMA-313 clinical trial evaluating Ultomiris (ravulizumab) in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The trial did not achieve statistical significance for its primary endpoint of event-free survival (EFS) through 26 weeks compared to placebo in adult and adolescent patients aged 12 years and older.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70775\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alexion&#039;s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend\" \/>\n<meta property=\"og:description\" content=\"Alexion, AstraZeneca plc&#039;s (NYSE: AZN) rare disease unit, announced top-line results from its Phase III ALXN1210-TMA-313 clinical trial evaluating Ultomiris (ravulizumab) in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The trial did not achieve statistical significance for its primary endpoint of event-free survival (EFS) through 26 weeks compared to placebo in adult and adolescent patients aged 12 years and older.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70775\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T10:02:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-28T10:02:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70775#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70775\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alexion&#8217;s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend\",\"datePublished\":\"2026-07-28T10:02:20+00:00\",\"dateModified\":\"2026-07-28T10:02:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70775\"},\"wordCount\":368,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Alexion\",\"AstraZeneca\",\"Clinical trial results\",\"NYSE:\u202fAZN\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70775#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70775\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70775\",\"name\":\"Alexion's Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-28T10:02:20+00:00\",\"dateModified\":\"2026-07-28T10:02:21+00:00\",\"description\":\"Alexion, AstraZeneca plc's (NYSE: AZN) rare disease unit, announced top-line results from its Phase III ALXN1210-TMA-313 clinical trial evaluating Ultomiris (ravulizumab) in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The trial did not achieve statistical significance for its primary endpoint of event-free survival (EFS) through 26 weeks compared to placebo in adult and adolescent patients aged 12 years and older.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70775#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70775\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70775#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alexion&#8217;s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alexion's Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend - Insight, China&#039;s Pharmaceutical Industry","description":"Alexion, AstraZeneca plc's (NYSE: AZN) rare disease unit, announced top-line results from its Phase III ALXN1210-TMA-313 clinical trial evaluating Ultomiris (ravulizumab) in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The trial did not achieve statistical significance for its primary endpoint of event-free survival (EFS) through 26 weeks compared to placebo in adult and adolescent patients aged 12 years and older.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70775","og_locale":"en_US","og_type":"article","og_title":"Alexion's Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend","og_description":"Alexion, AstraZeneca plc's (NYSE: AZN) rare disease unit, announced top-line results from its Phase III ALXN1210-TMA-313 clinical trial evaluating Ultomiris (ravulizumab) in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The trial did not achieve statistical significance for its primary endpoint of event-free survival (EFS) through 26 weeks compared to placebo in adult and adolescent patients aged 12 years and older.","og_url":"https:\/\/flcube.com\/?p=70775","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-28T10:02:20+00:00","article_modified_time":"2026-07-28T10:02:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70775#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70775"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alexion&#8217;s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend","datePublished":"2026-07-28T10:02:20+00:00","dateModified":"2026-07-28T10:02:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70775"},"wordCount":368,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Alexion","AstraZeneca","Clinical trial results","NYSE:\u202fAZN"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70775#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70775","url":"https:\/\/flcube.com\/?p=70775","name":"Alexion's Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-28T10:02:20+00:00","dateModified":"2026-07-28T10:02:21+00:00","description":"Alexion, AstraZeneca plc's (NYSE: AZN) rare disease unit, announced top-line results from its Phase III ALXN1210-TMA-313 clinical trial evaluating Ultomiris (ravulizumab) in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The trial did not achieve statistical significance for its primary endpoint of event-free survival (EFS) through 26 weeks compared to placebo in adult and adolescent patients aged 12 years and older.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70775#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70775"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70775#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alexion&#8217;s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70775"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70775\/revisions"}],"predecessor-version":[{"id":70776,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70775\/revisions\/70776"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}